Tysabri Study Participants To Undergo MRI, Physical In Search For Cause Of Adverse Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec and Elan are suspending Tysabri clinical trials and conducting MRIs and physicals on trial participants as part of their voluntary marketing suspension of the multiple sclerosis therapy, the companies said
You may also be interested in...
FDA Re-Approves Tysabri, Recommends Second-Line Use
Biogen Idec expects to re-launch the multiple sclerosis therapy in July.
FDA Re-Approves Tysabri, Recommends Second-Line Use
Biogen Idec expects to re-launch the multiple sclerosis therapy in July.
Copaxone Reaches MS Market Share High Following Tysabri Withdrawal
Teva’s multiple sclerosis therapy glatiramer gained the leading market position in both total and new prescriptions in March, the company says. Copaxone’s gains followed Biogen Idec/Elan’s marketing suspension of the competing MS therapy Tysabri and the addition of a liver damage warning to Biogen’s Avonex.